Deferasirox

Drug Profile

Deferasirox

Alternative Names: CGP-72670; Exjade; ICL-670; ICL-670A; Jadenu

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents; Cytochrome P 450 cyp2c8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase II Myelodysplastic syndromes; Thalassaemia
  • Discontinued Malaria

Most Recent Events

  • 15 Jul 2017 Phase-II clinical trials in Thalassaemia in Turkey (PO) (NCT02993224)
  • 05 Jul 2017 Novartis plans a phase II trial for Haemochromatosis (NCT03203850)
  • 19 May 2017 Sunnybrook Health Sciences Centre and Novartis terminates a phase II trial in Myelodysplastic syndromes (Combination therapy) in Canada (NCT02038816)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top